共 70 条
- [61] Nagata Y., Lan K.H., Zhou X., Et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts transtuzumab resistance in patients, Cancer Cell, 6, pp. 117-127, (2004)
- [62] Miller K.D., The role of ErbB inhibitors in trastuzumab resistance, Oncologist, 9, SUPPL. 3, pp. 16-19, (2004)
- [63] Yakes F.M., Chinratanalab W., Ritter C.A., Et al., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action, Cancer Res., 62, pp. 4132-4141, (2002)
- [64] Carney W.P., Neumann R., Lipton A., Et al., Potential clinical utility of serum HER-2/neu oncoprotein concentration in patients with breast cancer, Clin Chem., 49, pp. 1579-1598, (2003)
- [65] Hudelist G., Kostler W.J., Attems J., Et al., Her-2/neu-triggered intracellular tyrosine kinase activation: In vivo relevance of lig-and-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment, Br J Cancer, 89, pp. 983-991, (2003)
- [66] Marchetti P., Natural medicine: A "new frontier" in oncology?, Ann Oncol., 16, pp. 339-340, (2005)
- [67] Nelson R., Oleic acid suppresses overexpression of ER BB2 oncogene, Lancet Oncol., 6, (2005)
- [68] Xing X., Wang S.C., Xia W., Et al., The ets protein PEA5 suppresses HER-2/new overexpression and inhibits tumorigenesis, Nat. Med., 6, pp. 189-195, (2000)
- [69] Wang S.C., Hung M.C., Transcriptional targeting of the HER-2/neu oncogene, Drugs Today (Barc), 36, pp. 835-843, (2000)
- [70] Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M., Insulin-like growth factor-1 receptor signaling and resistance to transtuzumab (Herceptin), J Natl Cancer Inst., 93, pp. 1852-1857, (2001)